Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

This study is specifically looking for women aged 18 or older who have been diagnosed with a certain type of ovarian, fallopian tube, or peritoneal cancer (referred to as high-grade serous). Your cancer must have come back after your first round of chemotherapy, but critically, it should still respond well to platinum-based chemotherapy. A crucial part of joining this study is that your cancer cells must show high levels of a specific protein called folate receptor alpha (FRα), which will be checked with a special test.

There are also some important reasons why you might not be able to join. For example, if your cancer is a different type (like endometrioid or clear cell), or if you've already had many rounds of chemotherapy before or developed certain side effects like severe nerve damage. You also can't join if you have certain eye problems, severe blood clots, or if you are pregnant or breastfeeding. The study also needs to ensure that the bevacizumab treatment is suitable for you.

We would also need to confirm that you haven't received specific previous treatments, like mirvetuximab soravtansine or other targeted FRα drugs, and that you don't have certain other medical conditions, including untreated brain tumours or recent history of other cancers. You must also be willing to use effective contraception if you are able to become pregnant.

If you decide to join this study, you will be assigned to one of two groups. One group will receive mirvetuximab soravtansine plus bevacizumab, and the other group will receive bevacizumab alone. Both medicines are given through an IV (into a vein).

You will have regular hospital visits for treatments, check-ups, and tests like blood work, scans (to monitor your cancer), and physical exams. The exact schedule will depend on which group you are in and how you respond to the treatment. These visits are important for the research team to monitor your health and the effects of the treatment.

The total length of time you participate in the study will vary. You will continue treatment for as long as it is benefiting you and you are tolerating the study drugs well, or until your cancer starts to grow again. After your treatment ends, there will be follow-up appointments to check on your long-term health.

Throughout the study, you'll be asked to provide informed consent, which means you understand what's involved and agree to take part. Researchers will be available to answer any questions you have at any time.